Tirzepatide
Description
Tirzepatide is a revolutionary peptide, the first of its class to act as a dual agonist of GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This dual synergistic action significantly enhances glycemic control, appetite suppression, and metabolic optimization, often outperforming selective GLP-1 agonists in comparative studies.
Presentation: 5mg / 10mg / 30mg lyophilized vial.
Technical Specifications
- Name: Tirzepatide
- Sequence: YE-Aib-GTFTSD-Aib-SI-Aib-LDKIAQKAFVQWLIAGGPSSGAPPPS (with lipid modifications)
- Molecular Formula: C225H348N48O68
- Molecular Weight: ~4813.5 g/mol
- Appearance: White lyophilized powder
- Storage: Keep refrigerated (2-8°C).
Research & Scientific Literature
Tirzepatide mimics the action of two natural incretin hormones: GLP-1 and GIP. GLP-1 regulates appetite and caloric intake in the brain, while GIP complements this action by improving insulin secretion and lipid metabolism. By activating both receptors simultaneously, Tirzepatide achieves a "Twincretin" effect that results in superior efficacy in glucose regulation and weight reduction compared to single-receptor agonists.(1)
In extensive clinical trials (such as the SURMOUNT series), Tirzepatide has demonstrated unprecedented results in body weight reduction. Participants have experienced significant weight losses, often exceeding 20% of their initial weight, bringing it close to bariatric surgery results but through pharmacological intervention.(2)
In addition to weight loss, Tirzepatide improves multiple cardiovascular risk markers. A reduction in blood pressure, decrease in triglycerides and LDL cholesterol, and an increase in insulin sensitivity have been observed. This suggests significant long-term cardioprotective potential.(3)
Initially approved for the treatment of Type 2 Diabetes, Tirzepatide has shown superior ability to reduce HbA1c (glycosylated hemoglobin) levels compared to other standard treatments, including basal insulin. Its dual action improves pancreatic beta-cell function and insulin sensitivity.(4)
Research Disclaimer: The information regarding this compound is provided strictly for academic and scientific review. It is not intended for diagnostic, therapeutic, or clinical use in humans or animals. This is an investigational compound.
- Rosenstock, J., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet.
- Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine.
- Frias, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. The New England Journal of Medicine.
- Dahl, D., et al. (2022). Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA.